$VERU
Veru Inc

2021 Q3 Form 10-Q Financial Statement

#000086389421000009 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $15.65M $17.66M $10.32M
YoY Change 33.16% 71.05% 6.11%
Cost Of Revenue $3.337M $3.782M $3.803M
YoY Change 52.39% -0.53% 20.49%
Gross Profit $12.31M $13.87M $6.519M
YoY Change 28.76% 112.81% -0.79%
Gross Profit Margin 78.67% 78.58% 63.16%
Selling, General & Admin $5.925M $5.557M $3.475M
YoY Change 71.24% 59.88% -2.02%
% of Gross Profit 48.13% 40.05% 53.31%
Research & Development $8.256M $11.19M $4.436M
YoY Change 152.46% 152.19% -8.83%
% of Gross Profit 67.07% 80.65% 68.05%
Depreciation & Amortization $40.68K $21.00K $120.0K
YoY Change -66.1% -82.5% -7.69%
% of Gross Profit 0.33% 0.15% 1.84%
Operating Expenses $14.18M $16.74M $7.912M
YoY Change 110.7% 111.64% -5.96%
Operating Profit -$1.871M -$2.872M -$1.393M
YoY Change -166.12% 106.19% -24.38%
Interest Expense -$2.798M $1.288M $1.170M
YoY Change 67.53% 10.07% 7.19%
% of Operating Profit
Other Income/Expense, Net $18.47K -$2.694M -$1.392M
YoY Change -130.78% 93.54% 49.27%
Pretax Income -$4.651M -$5.566M -$2.785M
YoY Change -64.06% 99.86% 0.37%
Income Tax -$356.1K -$2.873M $240.5K
% Of Pretax Income
Net Earnings -$4.294M -$2.693M -$3.025M
YoY Change -63.7% -10.99% 9.06%
Net Earnings / Revenue -27.45% -15.25% -29.31%
Basic Earnings Per Share -$0.03 -$0.05
Diluted Earnings Per Share -$53.73K -$0.03 -$0.05
COMMON SHARES
Basic Shares Outstanding 79.85M 79.73M 66.73M
Diluted Shares Outstanding 79.73M 66.73M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.4M $123.2M $15.40M
YoY Change 799.7% 699.71% 92.5%
Cash & Equivalents $122.4M $123.2M $15.39M
Short-Term Investments
Other Short-Term Assets $10.03M $10.99M $2.100M
YoY Change 568.37% 423.34% 75.0%
Inventory $5.574M $6.946M $5.200M
Prepaid Expenses
Receivables $8.794M $8.314M $4.200M
Other Receivables $5.000M $5.000M -$100.0K
Total Short-Term Assets $151.8M $154.4M $26.90M
YoY Change 461.74% 474.0% 56.92%
LONG-TERM ASSETS
Property, Plant & Equipment $592.6K $392.0K $315.5K
YoY Change 89.52% 24.27% 0.24%
Goodwill $6.900M $6.900M
YoY Change 0.0%
Intangibles $4.049M $4.067M $19.93M
YoY Change -29.61% -79.6% -1.55%
Long-Term Investments
YoY Change
Other Assets $878.5K $880.9K $1.562M
YoY Change 14.67% -43.61% 128.35%
Total Long-Term Assets $26.39M $25.67M $38.30M
YoY Change 7.6% -32.98% 4.37%
TOTAL ASSETS
Total Short-Term Assets $151.8M $154.4M $26.90M
Total Long-Term Assets $26.39M $25.67M $38.30M
Total Assets $178.1M $180.1M $65.20M
YoY Change 245.62% 176.19% 21.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.410M $4.928M $3.800M
YoY Change 21.23% 29.68% 21.22%
Accrued Expenses $8.979M $7.719M $6.400M
YoY Change 83.25% 20.62% 64.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.246M $4.565M $7.000M
YoY Change -53.63% -34.79% 48.94%
Total Short-Term Liabilities $15.77M $17.21M $17.37M
YoY Change 7.06% -0.93% 48.95%
LONG-TERM LIABILITIES
Long-Term Debt $9.397M $7.100M $5.400M
YoY Change 67.81% 31.48% -14.29%
Other Long-Term Liabilities $14.99K $14.99K $800.0K
YoY Change -34.79% -98.13% 2566.67%
Total Long-Term Liabilities $14.99K $14.99K $6.200M
YoY Change -34.79% -99.76% 20566.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.77M $17.21M $17.37M
Total Long-Term Liabilities $14.99K $14.99K $6.200M
Total Liabilities $25.85M $25.10M $23.90M
YoY Change 20.62% 5.04% 25.1%
SHAREHOLDERS EQUITY
Retained Earnings -$81.80M -$77.50M
YoY Change -8.29%
Common Stock $821.5K $820.4K
YoY Change 14.03%
Preferred Stock
YoY Change
Treasury Stock (at cost) $7.807M $7.807M
YoY Change 0.0%
Treasury Stock Shares $2.184M $2.184M $2.184M
Shareholders Equity $152.3M $155.0M $41.28M
YoY Change
Total Liabilities & Shareholders Equity $178.1M $180.1M $65.20M
YoY Change 245.62% 176.19% 21.1%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$4.294M -$2.693M -$3.025M
YoY Change -63.7% -10.99% 9.06%
Depreciation, Depletion And Amortization $40.68K $21.00K $120.0K
YoY Change -66.1% -82.5% -7.69%
Cash From Operating Activities -$806.5K -$12.83M $3.340M
YoY Change 137.19% -484.27% -730.19%
INVESTING ACTIVITIES
Capital Expenditures -$222.2K -$144.4K -$20.00K
YoY Change 455.57% 622.1% -71.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$222.2K -$144.4K -$20.00K
YoY Change 455.57% 622.1% -71.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 232.3K -543.8K 9.520M
YoY Change -116.24% -105.71% 247.45%
NET CHANGE
Cash From Operating Activities -806.5K -12.83M 3.340M
Cash From Investing Activities -222.2K -144.4K -20.00K
Cash From Financing Activities 232.3K -543.8K 9.520M
Net Change In Cash -796.4K -13.52M 12.84M
YoY Change -56.0% -205.32% 500.0%
FREE CASH FLOW
Cash From Operating Activities -$806.5K -$12.83M $3.340M
Capital Expenditures -$222.2K -$144.4K -$20.00K
Free Cash Flow -$584.2K -$12.69M $3.360M
YoY Change 94.74% -477.68% -830.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0000863894
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-13602
dei Entity Registrant Name
EntityRegistrantName
Veru Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WI
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
39-1144397
dei Entity Address Address Line1
EntityAddressAddressLine1
48 NW 25th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33127
dei City Area Code
CityAreaCode
305
dei Local Phone Number
LocalPhoneNumber
509-6897
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
VERU
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79853748
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
123155968
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13588778
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8313543
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5227237
CY2021Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
5000000
CY2021Q2 us-gaap Inventory Net
InventoryNet
6945916
CY2020Q3 us-gaap Inventory Net
InventoryNet
6704134
CY2021Q2 veru Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
9546026
CY2020Q3 veru Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
613274
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1444081
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
881267
CY2021Q2 us-gaap Assets Current
AssetsCurrent
154405534
CY2020Q3 us-gaap Assets Current
AssetsCurrent
27014690
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
392012
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312691
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1069472
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1352315
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12379578
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9466800
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4066667
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5752127
CY2021Q2 us-gaap Goodwill
Goodwill
6878932
CY2020Q3 us-gaap Goodwill
Goodwill
6878932
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
880888
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
766120
CY2021Q2 us-gaap Assets
Assets
180073083
CY2020Q3 us-gaap Assets
Assets
51543675
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4927680
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2812673
CY2021Q2 veru Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2327323
CY2020Q3 veru Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
934110
CY2021Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2760029
CY2020Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2274396
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2095688
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1177126
CY2021Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
884917
CY2020Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
5841874
CY2021Q2 veru Residual Royalty Agreement Current
ResidualRoyaltyAgreementCurrent
3679871
CY2020Q3 veru Residual Royalty Agreement Current
ResidualRoyaltyAgreementCurrent
1100193
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
536449
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
586769
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17211957
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14727141
CY2021Q2 veru Residual Royalty Agreement Noncurrent
ResidualRoyaltyAgreementNoncurrent
7100145
CY2020Q3 veru Residual Royalty Agreement Noncurrent
ResidualRoyaltyAgreementNoncurrent
5617494
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
702993
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
990020
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
74724
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51543675
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17655592
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10321754
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45613068
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
74724
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14986
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22980
CY2021Q2 us-gaap Liabilities
Liabilities
25104805
CY2020Q3 us-gaap Liabilities
Liabilities
21432359
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
154000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
154000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82037452
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72047385
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79853748
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69863681
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
820375
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
720474
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
240039725
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126971518
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-581519
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-581519
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77503698
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89192552
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
2183704
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
2183704
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
7806605
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
7806605
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
154968278
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
30111316
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180073083
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30842874
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3782480
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3802636
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9995023
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9618163
CY2021Q2 us-gaap Gross Profit
GrossProfit
13873112
CY2020Q2 us-gaap Gross Profit
GrossProfit
6519118
us-gaap Gross Profit
GrossProfit
35618045
us-gaap Gross Profit
GrossProfit
21224711
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11188246
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4436496
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24438813
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13666730
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5556730
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3475474
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14745507
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11034904
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
16744976
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
7911970
us-gaap Operating Expenses
OperatingExpenses
39184320
us-gaap Operating Expenses
OperatingExpenses
24701634
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
18410158
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2871864
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1392852
us-gaap Operating Income Loss
OperatingIncomeLoss
14843883
us-gaap Operating Income Loss
OperatingIncomeLoss
-3476923
CY2021Q2 us-gaap Interest Expense
InterestExpense
1287525
CY2020Q2 us-gaap Interest Expense
InterestExpense
1169692
us-gaap Interest Expense
InterestExpense
3728259
us-gaap Interest Expense
InterestExpense
3476079
CY2021Q2 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-1372000
CY2020Q2 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-169000
us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-2029000
us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
-94000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34540
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-53334
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-170841
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63369
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2694065
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1392026
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5928100
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3633448
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5565929
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2784878
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8915783
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7110371
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2873063
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
240502
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2773071
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
685314
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
34759
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-810509
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
31114577
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692866
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
154968278
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
32333136
CY2019Q4 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
614498
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-3305101
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
29642533
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
681680
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
408632
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1227000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30619
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692866
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3025380
us-gaap Net Income Loss
NetIncomeLoss
11688854
us-gaap Net Income Loss
NetIncomeLoss
-7140990
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79729370
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66728782
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75054871
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65709139
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79729370
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66728782
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82807156
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65709139
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
30111316
CY2020Q4 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
785297
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
623819
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
17227701
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
48748133
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1002281
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
649275
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107942298
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2845981
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
155496006
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1900085
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
265053
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108099988
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
137690
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
3325180
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1538147
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6211000
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
680937
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12172999
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
356172
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6832
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3025380
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
41279107
us-gaap Net Income Loss
NetIncomeLoss
11688854
us-gaap Net Income Loss
NetIncomeLoss
-7140990
veru Depreciation And Other Amortization
DepreciationAndOtherAmortization
170713
veru Depreciation And Other Amortization
DepreciationAndOtherAmortization
347159
veru Operating Lease Right Of Use Assets Non Cash Change
OperatingLeaseRightOfUseAssetsNonCashChange
282843
veru Operating Lease Right Of Use Assets Non Cash Change
OperatingLeaseRightOfUseAssetsNonCashChange
240282
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2923628
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3476079
us-gaap Share Based Compensation
ShareBasedCompensation
3687663
us-gaap Share Based Compensation
ShareBasedCompensation
1981492
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
18410158
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2912778
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-198202
us-gaap Inventory Write Down
InventoryWriteDown
175085
us-gaap Inventory Write Down
InventoryWriteDown
227982
us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-2029000
us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-94000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-3000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
7500
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3083306
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-194471
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
416867
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1775018
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9610334
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4794
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2115007
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
648239
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2783696
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
556330
veru Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-337346
veru Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-243514
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14764556
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1588984
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
15000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
154416
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73444
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14845584
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73444
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
94000
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3719000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
415464
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1061442
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
836780
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1061442
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
555920
veru Proceeds From Issuance Of Common Stock Under Purchase Agreement
ProceedsFromIssuanceOfCommonStockUnderPurchaseAgreement
13399999
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
14283
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9444
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109486162
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10761699
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
109567190
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9099271
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13588778
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6295152
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
123155968
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15394423
us-gaap Interest Paid Net
InterestPaidNet
6651887
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1253233
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
5000000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
390931
veru Noncash Or Part Noncash Acquisition Shares Issued For Services
NoncashOrPartNoncashAcquisitionSharesIssuedForServices
680937
veru Increase In Other Assets From Accrued Expenses
IncreaseInOtherAssetsFromAccruedExpenses
50284
veru Accrued Stock Issuance Costs
AccruedStockIssuanceCosts
20000
us-gaap Basis Of Accounting
BasisOfAccounting
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 1 – Basis of Presentation</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying unaudited interim condensed consolidated financial statements for Veru Inc. (“we,” “our,” “us,” “Veru” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, these statements do not include all the disclosures normally required by U.S. GAAP for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020. The accompanying condensed consolidated balance sheet as of September 30, 2020 has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations for the three and nine months ended June 30, 2021 and cash flows for the nine months ended June 30, 2021 are not necessarily indicative of the results to be expected for any future period or for the fiscal year ending </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">September 30</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2021. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Principles of consolidation and nature of operations</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: Veru Inc. is </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">referred to in these notes collectively with its subsidiaries as “we,” “our,” “us,” “Veru” or the “Company.” </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The consolidated financial statements include the accounts of Veru and its wholly owned subsidiaries, Aspen Park Pharmaceuticals, Inc. (APP) and The Female Health Company Limited, and The Female Health Company Limited’s wholly owned subsidiary, The Female Health Company (UK) plc (The Female Health Company Limited and The Female Health Company (UK) plc, collectively, the “U.K. subsidiary”), and The Female Health Company (UK) plc’s wholly owned subsidiary, The Female Health Company (M) SDN.BHD (the “Malaysia subsidiary”). All significant intercompany transactions and accounts have been eliminated in consolidation. The Company is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers. The Company has multiple drug products under clinical development. During fiscal 2020, the Sexual Health Business segment also included PREBOOST® 4% benzocaine medicated individual wipe for the treatment of premature ejaculation. The PREBOOST® business was sold on December 8, 2020. See Note 2 for additional information. Most of the Company’s net revenues during the three and nine months ended June 30, 2021 and 2020 were derived from sales of the FC2 Female Condom/FC2 Internal Condom® (FC2), an FDA-approved product for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Reclassifications</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Certain prior period amounts on the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These reclassifications had no effect on </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the results of operations or financial position for any period presented.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Other comprehensive income (loss)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income (loss). Although certain changes in assets and liabilities, such as foreign currency translation adjustments, are reported as a separate component of the equity section of the accompanying unaudited condensed consolidated balance sheets, these items, along with net income (loss), are components of other comprehensive loss. For the three and nine months ended June 30, 2021 and 2020, comprehensive income (loss) is equivalent to the reported net income (loss).</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Recently adopted accounting pronouncements</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326). This ASU introduces a new accounting model, the Current Expected Credit Losses model (CECL), which could result in earlier recognition of credit losses and additional disclosures related to credit risk. The CECL model requires the Company to use a forward-looking expected credit loss impairment methodology for the recognition of credit losses for financial instruments at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current U.S. GAAP, which generally require that a loss be incurred before it is recognized. The new standard also applies to receivables arising from revenue transactions such as accounts receivable. The Company adopted ASU 2016-13 on a modified-retrospective basis effective October 1, 2020. The adoption of ASU 2016-13 did not impact our consolidated financial statements and related disclosures.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment. The purpose of ASU 2017-04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The Company adopted ASU 2017-04 on a prospective basis effective October 1, 2020. The adoption of ASU 2017-04 did not impact our consolidated financial statements and related disclosures.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Change to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The Company adopted ASU 2018-13 on a retrospective basis effective October 1, 2020. The adoption of ASU 2018-13 did not impact our financial position, results of operations, or cash flows as it modified disclosure requirements only.</span></p><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span>
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Reclassifications</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Certain prior period amounts on the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These reclassifications had no effect on </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the results of operations or financial position for any period presented.</span>
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4182000
CY2019Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3625000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
2029000
CY2021Q2 us-gaap Revenues
Revenues
17655592
CY2020Q2 us-gaap Revenues
Revenues
10321754
us-gaap Revenues
Revenues
45613068
us-gaap Revenues
Revenues
30842874
CY2021Q2 us-gaap Revenues
Revenues
17655592
CY2020Q2 us-gaap Revenues
Revenues
10321754
us-gaap Revenues
Revenues
45613068
us-gaap Revenues
Revenues
30842874
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
699000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6000
CY2021Q2 us-gaap Accounts Receivable Gross
AccountsReceivableGross
8441224
CY2020Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
5332786
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
22643
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
25643
CY2021Q2 veru Allowance For Sales And Payment Term Discounts
AllowanceForSalesAndPaymentTermDiscounts
105038
CY2020Q3 veru Allowance For Sales And Payment Term Discounts
AllowanceForSalesAndPaymentTermDiscounts
79906
CY2021Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
8313543
CY2020Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
5227237
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
0
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
0
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3580423
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3972435
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3855224
CY2021Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
327550
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3542533
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
392012
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312691
CY2021Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
4400000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
333333
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4066667
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2900000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1047873
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1852127
CY2020Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
6800000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1047873
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5752127
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
79000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
96000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
237000
CY2020Q3 us-gaap Goodwill
Goodwill
6900000
CY2021Q2 us-gaap Goodwill
Goodwill
6900000
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2020Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
782169
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1400039
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2488747
CY2021Q2 us-gaap Accretion Expense
AccretionExpense
952276
CY2020Q2 us-gaap Accretion Expense
AccretionExpense
369138
us-gaap Accretion Expense
AccretionExpense
2295313
us-gaap Accretion Expense
AccretionExpense
928835
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
7699
CY2020Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18385
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
32907
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
58497
CY2021Q2 us-gaap Interest Expense
InterestExpense
1287525
CY2020Q2 us-gaap Interest Expense
InterestExpense
1169692
us-gaap Interest Expense
InterestExpense
3728259
us-gaap Interest Expense
InterestExpense
3476079
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7419354
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
15.50
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107900000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1900085
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
685314
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3687663
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1981492
veru Stock Option Conversion Ratio
StockOptionConversionRatio
1
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
415000
veru Stock Issued During Period Shares Stock Options Exercised Cashless Exercise
StockIssuedDuringPeriodSharesStockOptionsExercisedCashlessExercise
0
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
117000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2178
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2178
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6535
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6535
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
611
CY2020Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1238
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2327
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4097
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
136140
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
124326
us-gaap Operating Lease Cost
OperatingLeaseCost
408079
us-gaap Operating Lease Cost
OperatingLeaseCost
378006
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1863
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1863
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5589
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5589
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
48061
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
24213
us-gaap Variable Lease Cost
VariableLeaseCost
124283
us-gaap Variable Lease Cost
VariableLeaseCost
91349
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
44844
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
45382
us-gaap Sublease Income
SubleaseIncome
134533
us-gaap Sublease Income
SubleaseIncome
135071
CY2021Q2 us-gaap Lease Cost
LeaseCost
144009
CY2020Q2 us-gaap Lease Cost
LeaseCost
108436
us-gaap Lease Cost
LeaseCost
412280
us-gaap Lease Cost
LeaseCost
350505
us-gaap Operating Lease Payments
OperatingLeasePayments
497000
us-gaap Operating Lease Payments
OperatingLeasePayments
350000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.115
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.115
CY2021Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M12D
CY2020Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.139
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.139
CY2021Q2 veru Product Liability Insurance Coverage Amount
ProductLiabilityInsuranceCoverageAmount
20000000.0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1168845
CY2020Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-584825
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1872314
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1493179
CY2021Q2 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-90502
CY2020Q2 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-45268
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
144971
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-115615
CY2021Q2 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-2807
CY2020Q2 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
332230
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-2807
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
335869
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
53011
veru Effective Income Tax Rate Reconciliation Effect Of Warrants Exercised
EffectiveIncomeTaxRateReconciliationEffectOfWarrantsExercised
-2038919
CY2021Q2 veru Cares Act Effective Income Tax Rate Reconciliation Effect Of Paycheck Protection Program Funds
CaresActEffectiveIncomeTaxRateReconciliationEffectOfPaycheckProtectionProgramFunds
-8784
veru Cares Act Effective Income Tax Rate Reconciliation Effect Of Paycheck Protection Program Funds
CaresActEffectiveIncomeTaxRateReconciliationEffectOfPaycheckProtectionProgramFunds
113442
CY2021Q2 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
919415
us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
919415
CY2021Q2 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-3716935
CY2020Q2 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-16478
us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-3744512
us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
49908
CY2021Q2 veru Income Tax Reconciliation Effect Of Global Intangible Low Taxed Income
IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome
78626
CY2020Q2 veru Income Tax Reconciliation Effect Of Global Intangible Low Taxed Income
IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome
85522
veru Income Tax Reconciliation Effect Of Global Intangible Low Taxed Income
IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome
148383
veru Income Tax Reconciliation Effect Of Global Intangible Low Taxed Income
IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome
101642
CY2021Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2834482
CY2020Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
415449
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1828730
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1097900
CY2021Q2 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
50538
CY2020Q2 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
53872
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
51626
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
54094
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2873063
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
240502
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2773071
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30619
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
8269223
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
8759589
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
1647082
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
1682104
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
15259909
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
11655853
CY2021Q2 veru Deferred Tax Assets Foreign Capital Allowance
DeferredTaxAssetsForeignCapitalAllowance
149371
CY2020Q3 veru Deferred Tax Assets Foreign Capital Allowance
DeferredTaxAssetsForeignCapitalAllowance
113522
CY2021Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
919415
CY2021Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
770598
CY2020Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1255983
CY2021Q2 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
1165193
CY2020Q3 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
850248
CY2021Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
654354
CY2020Q3 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
195265
CY2021Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29146130
CY2020Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24785980
CY2021Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15903470
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14074740
CY2021Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
13242660
CY2020Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
10711240
CY2021Q2 veru Deferred Tax Liabilities In Process R And D
DeferredTaxLiabilitiesInProcessRAndD
882427
CY2020Q3 veru Deferred Tax Liabilities In Process R And D
DeferredTaxLiabilitiesInProcessRAndD
882427
CY2020Q3 veru Deferred Tax Liabilities Developed Technology
DeferredTaxLiabilitiesDevelopedTechnology
369237
CY2021Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
37711
CY2020Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
49832
CY2021Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
937806
CY2020Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1319164
CY2021Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
12304854
CY2020Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9392076
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
499783
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2020Q2 veru Reduction Of Research And Development Expense Cares Act
ReductionOfResearchAndDevelopmentExpenseCaresAct
120000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692866
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3025380
us-gaap Net Income Loss
NetIncomeLoss
11688854
us-gaap Net Income Loss
NetIncomeLoss
-7140990
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79729370
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66728782
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75054871
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65709139
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7752285
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79729370
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66728782
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82807156
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65709139
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12379578
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9466800
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
74724
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
74724
CY2020Q2 veru Proceeds From Ppp Loan Cares Act
ProceedsFromPppLoanCaresAct
540000
veru Reduction Of Selling General And Administrative Expense Cares Act
ReductionOfSellingGeneralAndAdministrativeExpenseCaresAct
420000
CY2020Q2 veru Reduction Of Selling General And Administrative Expense Cares Act
ReductionOfSellingGeneralAndAdministrativeExpenseCaresAct
420000
veru Reduction Of Research And Development Expense Cares Act
ReductionOfResearchAndDevelopmentExpenseCaresAct
120000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
819000

Files In Submission

Name View Source Status
0000863894-21-000009-index-headers.html Edgar Link pending
0000863894-21-000009-index.html Edgar Link pending
0000863894-21-000009.txt Edgar Link pending
0000863894-21-000009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
veru-20210630.xsd Edgar Link pending
veru-20210630x10q.htm Edgar Link pending
veru-20210630x10q_htm.xml Edgar Link completed
veru-20210630xex31_1.htm Edgar Link pending
veru-20210630xex31_2.htm Edgar Link pending
veru-20210630xex32_1.htm Edgar Link pending
veru-20210630_cal.xml Edgar Link unprocessable
veru-20210630_def.xml Edgar Link unprocessable
veru-20210630_lab.xml Edgar Link unprocessable
veru-20210630_pre.xml Edgar Link unprocessable